Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of XLH rickets~* Fasting serum calcium of 10.7 mg/dl or less~* Fasting PTH greater than 40 nleq/ml and less than 120 nleq/ml in the mid-molecule PTH assay at screening (upper limit of normal is 25 nleq/ml)~* Willing and able to participate in the trial~* Taking stable dose of standard therapy for XLH rickets for at least 2 months prior to study entry~* Concomitant therapy for XLH rickets will not be an exclusion criteria~* Parent or guardian willing to provide informed consent, if applicable~Exclusion Criteria:~* Concomitant kidney failure (estimated creatinine clearance less than 60 cc/min or serum creatinine greater than 1.5 mg/dl)~* Serum 25-hydroxy vitamin D less than 20 ng/ml. Participants meeting this criterion will receive vitamin D3 supplementation for 3 months and then be rescreened.~* Unable to comply with protocol and appropriate follow-up visits~* Treatment with agents that may affect skeletal metabolism, such as glucocorticoids and anticonvulsants

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
- 2 (Type: PLACEBO_COMPARATOR): Participants given placebo capsule to match for comparison

Based on this trial design, predict the completion outcome and termination type (if applicable).